nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—SLC15A1—Lisinopril—systemic scleroderma	0.409	0.572	CbGbCtD
Methyldopa—SLC15A1—Captopril—systemic scleroderma	0.306	0.428	CbGbCtD
Methyldopa—Hepatitis—Mycophenolic acid—systemic scleroderma	0.000726	0.00255	CcSEcCtD
Methyldopa—Abdominal distension—Mycophenolate mofetil—systemic scleroderma	0.000721	0.00253	CcSEcCtD
Methyldopa—Connective tissue disorder—Mycophenolic acid—systemic scleroderma	0.000714	0.00251	CcSEcCtD
Methyldopa—Jaundice—Lisinopril—systemic scleroderma	0.00071	0.00249	CcSEcCtD
Methyldopa—Cardiac disorder—Leflunomide—systemic scleroderma	0.000706	0.00248	CcSEcCtD
Methyldopa—Pancreatitis—Mycophenolate mofetil—systemic scleroderma	0.000702	0.00247	CcSEcCtD
Methyldopa—Angina pectoris—Mycophenolate mofetil—systemic scleroderma	0.000697	0.00245	CcSEcCtD
Methyldopa—Hepatobiliary disease—Lisinopril—systemic scleroderma	0.000689	0.00242	CcSEcCtD
Methyldopa—Mediastinal disorder—Leflunomide—systemic scleroderma	0.000686	0.00241	CcSEcCtD
Methyldopa—Myalgia—Captopril—systemic scleroderma	0.000684	0.0024	CcSEcCtD
Methyldopa—Arthralgia—Captopril—systemic scleroderma	0.000684	0.0024	CcSEcCtD
Methyldopa—Body temperature increased—Pentoxifylline—systemic scleroderma	0.000684	0.0024	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Mometasone—systemic scleroderma	0.000681	0.00239	CcSEcCtD
Methyldopa—Pancytopenia—Mycophenolate mofetil—systemic scleroderma	0.00068	0.00239	CcSEcCtD
Methyldopa—Agranulocytosis—Lisinopril—systemic scleroderma	0.00068	0.00239	CcSEcCtD
Methyldopa—Cardiac disorder—Mycophenolic acid—systemic scleroderma	0.000674	0.00237	CcSEcCtD
Methyldopa—Paraesthesia—Mometasone—systemic scleroderma	0.000671	0.00236	CcSEcCtD
Methyldopa—Mental disorder—Leflunomide—systemic scleroderma	0.000667	0.00234	CcSEcCtD
Methyldopa—Bradycardia—Lisinopril—systemic scleroderma	0.000666	0.00234	CcSEcCtD
Methyldopa—Vasculitis—Methotrexate—systemic scleroderma	0.000662	0.00233	CcSEcCtD
Methyldopa—Erectile dysfunction—Mycophenolate mofetil—systemic scleroderma	0.000659	0.00232	CcSEcCtD
Methyldopa—Angiopathy—Mycophenolic acid—systemic scleroderma	0.000659	0.00231	CcSEcCtD
Methyldopa—Mediastinal disorder—Mycophenolic acid—systemic scleroderma	0.000654	0.0023	CcSEcCtD
Methyldopa—Hepatitis—Lisinopril—systemic scleroderma	0.000654	0.0023	CcSEcCtD
Methyldopa—Flatulence—Leflunomide—systemic scleroderma	0.000653	0.00229	CcSEcCtD
Methyldopa—Weight increased—Mycophenolate mofetil—systemic scleroderma	0.000652	0.00229	CcSEcCtD
Methyldopa—Thrombocytopenia—Captopril—systemic scleroderma	0.000642	0.00226	CcSEcCtD
Methyldopa—Infestation—Mycophenolate mofetil—systemic scleroderma	0.000638	0.00224	CcSEcCtD
Methyldopa—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	0.000638	0.00224	CcSEcCtD
Methyldopa—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.000638	0.00224	CcSEcCtD
Methyldopa—Mental disorder—Mycophenolic acid—systemic scleroderma	0.000636	0.00223	CcSEcCtD
Methyldopa—Leukopenia—Azathioprine—systemic scleroderma	0.000628	0.00221	CcSEcCtD
Methyldopa—Flatulence—Mycophenolic acid—systemic scleroderma	0.000623	0.00219	CcSEcCtD
Methyldopa—Jaundice—Mycophenolate mofetil—systemic scleroderma	0.000622	0.00219	CcSEcCtD
Methyldopa—Asthenia—Pentoxifylline—systemic scleroderma	0.000621	0.00218	CcSEcCtD
Methyldopa—Cardiac failure congestive—Prednisone—systemic scleroderma	0.000619	0.00218	CcSEcCtD
Methyldopa—Hepatobiliary disease—Mycophenolate mofetil—systemic scleroderma	0.000604	0.00212	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.000598	0.0021	CcSEcCtD
Methyldopa—Arthralgia—Azathioprine—systemic scleroderma	0.000597	0.0021	CcSEcCtD
Methyldopa—Myalgia—Azathioprine—systemic scleroderma	0.000597	0.0021	CcSEcCtD
Methyldopa—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.000596	0.00209	CcSEcCtD
Methyldopa—Angiopathy—Lisinopril—systemic scleroderma	0.000593	0.00208	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.000593	0.00208	CcSEcCtD
Methyldopa—Leukopenia—Leflunomide—systemic scleroderma	0.000593	0.00208	CcSEcCtD
Methyldopa—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000592	0.00208	CcSEcCtD
Methyldopa—Body temperature increased—Mometasone—systemic scleroderma	0.000591	0.00207	CcSEcCtD
Methyldopa—Mediastinal disorder—Lisinopril—systemic scleroderma	0.000589	0.00207	CcSEcCtD
Methyldopa—Paraesthesia—Captopril—systemic scleroderma	0.000589	0.00207	CcSEcCtD
Methyldopa—Bradycardia—Mycophenolate mofetil—systemic scleroderma	0.000583	0.00205	CcSEcCtD
Methyldopa—Gynaecomastia—Methotrexate—systemic scleroderma	0.000578	0.00203	CcSEcCtD
Methyldopa—Hepatitis—Mycophenolate mofetil—systemic scleroderma	0.000573	0.00201	CcSEcCtD
Methyldopa—Mental disorder—Lisinopril—systemic scleroderma	0.000573	0.00201	CcSEcCtD
Methyldopa—Dizziness—Pentoxifylline—systemic scleroderma	0.000573	0.00201	CcSEcCtD
Methyldopa—Infection—Azathioprine—systemic scleroderma	0.000569	0.002	CcSEcCtD
Methyldopa—Leukopenia—Mycophenolic acid—systemic scleroderma	0.000566	0.00199	CcSEcCtD
Methyldopa—Arthralgia—Leflunomide—systemic scleroderma	0.000564	0.00198	CcSEcCtD
Methyldopa—Myalgia—Leflunomide—systemic scleroderma	0.000564	0.00198	CcSEcCtD
Methyldopa—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.000563	0.00198	CcSEcCtD
Methyldopa—Constipation—Captopril—systemic scleroderma	0.000561	0.00197	CcSEcCtD
Methyldopa—Flatulence—Lisinopril—systemic scleroderma	0.000561	0.00197	CcSEcCtD
Methyldopa—Thrombocytopenia—Azathioprine—systemic scleroderma	0.000561	0.00197	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00056	0.00197	CcSEcCtD
Methyldopa—Skin disorder—Azathioprine—systemic scleroderma	0.000556	0.00195	CcSEcCtD
Methyldopa—Vomiting—Pentoxifylline—systemic scleroderma	0.00055	0.00193	CcSEcCtD
Methyldopa—Psychotic disorder—Prednisone—systemic scleroderma	0.000548	0.00193	CcSEcCtD
Methyldopa—Rash—Pentoxifylline—systemic scleroderma	0.000546	0.00192	CcSEcCtD
Methyldopa—Dermatitis—Pentoxifylline—systemic scleroderma	0.000545	0.00192	CcSEcCtD
Methyldopa—Headache—Pentoxifylline—systemic scleroderma	0.000542	0.00191	CcSEcCtD
Methyldopa—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000538	0.00189	CcSEcCtD
Methyldopa—Myalgia—Mycophenolic acid—systemic scleroderma	0.000538	0.00189	CcSEcCtD
Methyldopa—Infection—Leflunomide—systemic scleroderma	0.000537	0.00189	CcSEcCtD
Methyldopa—Asthenia—Mometasone—systemic scleroderma	0.000536	0.00188	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000534	0.00188	CcSEcCtD
Methyldopa—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000532	0.00187	CcSEcCtD
Methyldopa—Nervous system disorder—Leflunomide—systemic scleroderma	0.00053	0.00186	CcSEcCtD
Methyldopa—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000529	0.00186	CcSEcCtD
Methyldopa—Skin disorder—Leflunomide—systemic scleroderma	0.000525	0.00185	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000522	0.00183	CcSEcCtD
Methyldopa—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.00052	0.00183	CcSEcCtD
Methyldopa—Body temperature increased—Captopril—systemic scleroderma	0.000519	0.00182	CcSEcCtD
Methyldopa—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000516	0.00181	CcSEcCtD
Methyldopa—Oedema—Mycophenolic acid—systemic scleroderma	0.000516	0.00181	CcSEcCtD
Methyldopa—Nausea—Pentoxifylline—systemic scleroderma	0.000514	0.00181	CcSEcCtD
Methyldopa—Infection—Mycophenolic acid—systemic scleroderma	0.000513	0.0018	CcSEcCtD
Methyldopa—Diarrhoea—Mometasone—systemic scleroderma	0.000511	0.0018	CcSEcCtD
Methyldopa—Leukopenia—Lisinopril—systemic scleroderma	0.00051	0.00179	CcSEcCtD
Methyldopa—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000506	0.00178	CcSEcCtD
Methyldopa—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000505	0.00177	CcSEcCtD
Methyldopa—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000502	0.00176	CcSEcCtD
Methyldopa—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000501	0.00176	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000494	0.00174	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000493	0.00173	CcSEcCtD
Methyldopa—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.000492	0.00173	CcSEcCtD
Methyldopa—Abdominal distension—Prednisone—systemic scleroderma	0.000489	0.00172	CcSEcCtD
Methyldopa—Paraesthesia—Leflunomide—systemic scleroderma	0.000486	0.00171	CcSEcCtD
Methyldopa—Myalgia—Lisinopril—systemic scleroderma	0.000485	0.0017	CcSEcCtD
Methyldopa—Arthralgia—Lisinopril—systemic scleroderma	0.000485	0.0017	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000481	0.00169	CcSEcCtD
Methyldopa—Pancreatitis—Prednisone—systemic scleroderma	0.000476	0.00167	CcSEcCtD
Methyldopa—Vomiting—Mometasone—systemic scleroderma	0.000475	0.00167	CcSEcCtD
Methyldopa—Rash—Mometasone—systemic scleroderma	0.000471	0.00165	CcSEcCtD
Methyldopa—Asthenia—Captopril—systemic scleroderma	0.000471	0.00165	CcSEcCtD
Methyldopa—Dermatitis—Mometasone—systemic scleroderma	0.000471	0.00165	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00047	0.00165	CcSEcCtD
Methyldopa—Headache—Mometasone—systemic scleroderma	0.000468	0.00164	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000467	0.00164	CcSEcCtD
Methyldopa—Oedema—Lisinopril—systemic scleroderma	0.000465	0.00163	CcSEcCtD
Methyldopa—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000463	0.00163	CcSEcCtD
Methyldopa—Constipation—Leflunomide—systemic scleroderma	0.000462	0.00162	CcSEcCtD
Methyldopa—Infection—Lisinopril—systemic scleroderma	0.000462	0.00162	CcSEcCtD
Methyldopa—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000455	0.0016	CcSEcCtD
Methyldopa—Body temperature increased—Azathioprine—systemic scleroderma	0.000453	0.00159	CcSEcCtD
Methyldopa—Skin disorder—Lisinopril—systemic scleroderma	0.000451	0.00159	CcSEcCtD
Methyldopa—Diarrhoea—Captopril—systemic scleroderma	0.000449	0.00158	CcSEcCtD
Methyldopa—Erectile dysfunction—Prednisone—systemic scleroderma	0.000447	0.00157	CcSEcCtD
Methyldopa—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000447	0.00157	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000445	0.00156	CcSEcCtD
Methyldopa—Nausea—Mometasone—systemic scleroderma	0.000444	0.00156	CcSEcCtD
Methyldopa—Weight increased—Prednisone—systemic scleroderma	0.000442	0.00155	CcSEcCtD
Methyldopa—Constipation—Mycophenolic acid—systemic scleroderma	0.000441	0.00155	CcSEcCtD
Methyldopa—Dizziness—Captopril—systemic scleroderma	0.000434	0.00152	CcSEcCtD
Methyldopa—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000433	0.00152	CcSEcCtD
Methyldopa—Body temperature increased—Leflunomide—systemic scleroderma	0.000428	0.0015	CcSEcCtD
Methyldopa—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000425	0.00149	CcSEcCtD
Methyldopa—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000425	0.00149	CcSEcCtD
Methyldopa—Breast disorder—Methotrexate—systemic scleroderma	0.000424	0.00149	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000423	0.00149	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000423	0.00148	CcSEcCtD
Methyldopa—Hypersensitivity—Azathioprine—systemic scleroderma	0.000422	0.00148	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000422	0.00148	CcSEcCtD
Methyldopa—Paraesthesia—Lisinopril—systemic scleroderma	0.000417	0.00147	CcSEcCtD
Methyldopa—Vomiting—Captopril—systemic scleroderma	0.000417	0.00147	CcSEcCtD
Methyldopa—Rash—Captopril—systemic scleroderma	0.000414	0.00145	CcSEcCtD
Methyldopa—Dermatitis—Captopril—systemic scleroderma	0.000413	0.00145	CcSEcCtD
Methyldopa—Headache—Captopril—systemic scleroderma	0.000411	0.00144	CcSEcCtD
Methyldopa—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000408	0.00143	CcSEcCtD
Methyldopa—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000407	0.00143	CcSEcCtD
Methyldopa—Infection—Mycophenolate mofetil—systemic scleroderma	0.000404	0.00142	CcSEcCtD
Methyldopa—Eosinophilia—Methotrexate—systemic scleroderma	0.000402	0.00141	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000401	0.00141	CcSEcCtD
Methyldopa—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000399	0.0014	CcSEcCtD
Methyldopa—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000399	0.0014	CcSEcCtD
Methyldopa—Hypersensitivity—Leflunomide—systemic scleroderma	0.000398	0.0014	CcSEcCtD
Methyldopa—Pancreatitis—Methotrexate—systemic scleroderma	0.000398	0.0014	CcSEcCtD
Methyldopa—Constipation—Lisinopril—systemic scleroderma	0.000397	0.0014	CcSEcCtD
Methyldopa—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000395	0.00139	CcSEcCtD
Methyldopa—Bradycardia—Prednisone—systemic scleroderma	0.000395	0.00139	CcSEcCtD
Methyldopa—Diarrhoea—Azathioprine—systemic scleroderma	0.000392	0.00138	CcSEcCtD
Methyldopa—Nausea—Captopril—systemic scleroderma	0.00039	0.00137	CcSEcCtD
Methyldopa—Asthenia—Leflunomide—systemic scleroderma	0.000388	0.00136	CcSEcCtD
Methyldopa—Pancytopenia—Methotrexate—systemic scleroderma	0.000385	0.00135	CcSEcCtD
Methyldopa—Connective tissue disorder—Prednisone—systemic scleroderma	0.000382	0.00134	CcSEcCtD
Methyldopa—Dizziness—Azathioprine—systemic scleroderma	0.000379	0.00133	CcSEcCtD
Methyldopa—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000374	0.00131	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000371	0.0013	CcSEcCtD
Methyldopa—Asthenia—Mycophenolic acid—systemic scleroderma	0.00037	0.0013	CcSEcCtD
Methyldopa—Diarrhoea—Leflunomide—systemic scleroderma	0.00037	0.0013	CcSEcCtD
Methyldopa—Body temperature increased—Lisinopril—systemic scleroderma	0.000367	0.00129	CcSEcCtD
Methyldopa—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000366	0.00128	CcSEcCtD
Methyldopa—Vomiting—Azathioprine—systemic scleroderma	0.000364	0.00128	CcSEcCtD
Methyldopa—Infestation—Methotrexate—systemic scleroderma	0.000362	0.00127	CcSEcCtD
Methyldopa—Infestation NOS—Methotrexate—systemic scleroderma	0.000362	0.00127	CcSEcCtD
Methyldopa—Rash—Azathioprine—systemic scleroderma	0.000361	0.00127	CcSEcCtD
Methyldopa—Dermatitis—Azathioprine—systemic scleroderma	0.000361	0.00127	CcSEcCtD
Methyldopa—Headache—Azathioprine—systemic scleroderma	0.000359	0.00126	CcSEcCtD
Methyldopa—Dizziness—Leflunomide—systemic scleroderma	0.000358	0.00126	CcSEcCtD
Methyldopa—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000353	0.00124	CcSEcCtD
Methyldopa—Angiopathy—Prednisone—systemic scleroderma	0.000352	0.00124	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000351	0.00123	CcSEcCtD
Methyldopa—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000348	0.00122	CcSEcCtD
Methyldopa—Vomiting—Leflunomide—systemic scleroderma	0.000344	0.00121	CcSEcCtD
Methyldopa—Hypersensitivity—Lisinopril—systemic scleroderma	0.000342	0.0012	CcSEcCtD
Methyldopa—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000342	0.0012	CcSEcCtD
Methyldopa—Dizziness—Mycophenolic acid—systemic scleroderma	0.000341	0.0012	CcSEcCtD
Methyldopa—Rash—Leflunomide—systemic scleroderma	0.000341	0.0012	CcSEcCtD
Methyldopa—Dermatitis—Leflunomide—systemic scleroderma	0.000341	0.0012	CcSEcCtD
Methyldopa—Mental disorder—Prednisone—systemic scleroderma	0.00034	0.0012	CcSEcCtD
Methyldopa—Nausea—Azathioprine—systemic scleroderma	0.00034	0.00119	CcSEcCtD
Methyldopa—Headache—Leflunomide—systemic scleroderma	0.000339	0.00119	CcSEcCtD
Methyldopa—Agranulocytosis—Methotrexate—systemic scleroderma	0.000337	0.00119	CcSEcCtD
Methyldopa—Asthenia—Lisinopril—systemic scleroderma	0.000333	0.00117	CcSEcCtD
Methyldopa—Vomiting—Mycophenolic acid—systemic scleroderma	0.000328	0.00115	CcSEcCtD
Methyldopa—Rash—Mycophenolic acid—systemic scleroderma	0.000325	0.00114	CcSEcCtD
Methyldopa—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000325	0.00114	CcSEcCtD
Methyldopa—Hepatitis—Methotrexate—systemic scleroderma	0.000325	0.00114	CcSEcCtD
Methyldopa—Headache—Mycophenolic acid—systemic scleroderma	0.000323	0.00114	CcSEcCtD
Methyldopa—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000322	0.00113	CcSEcCtD
Methyldopa—Nausea—Leflunomide—systemic scleroderma	0.000321	0.00113	CcSEcCtD
Methyldopa—Diarrhoea—Lisinopril—systemic scleroderma	0.000318	0.00112	CcSEcCtD
Methyldopa—Dizziness—Lisinopril—systemic scleroderma	0.000307	0.00108	CcSEcCtD
Methyldopa—Nausea—Mycophenolic acid—systemic scleroderma	0.000306	0.00108	CcSEcCtD
Methyldopa—Cardiac disorder—Methotrexate—systemic scleroderma	0.000301	0.00106	CcSEcCtD
Methyldopa—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.0003	0.00105	CcSEcCtD
Methyldopa—Vomiting—Lisinopril—systemic scleroderma	0.000295	0.00104	CcSEcCtD
Methyldopa—Angiopathy—Methotrexate—systemic scleroderma	0.000295	0.00103	CcSEcCtD
Methyldopa—Rash—Lisinopril—systemic scleroderma	0.000293	0.00103	CcSEcCtD
Methyldopa—Dermatitis—Lisinopril—systemic scleroderma	0.000293	0.00103	CcSEcCtD
Methyldopa—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000293	0.00103	CcSEcCtD
Methyldopa—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000292	0.00103	CcSEcCtD
Methyldopa—Headache—Lisinopril—systemic scleroderma	0.000291	0.00102	CcSEcCtD
Methyldopa—Myalgia—Prednisone—systemic scleroderma	0.000288	0.00101	CcSEcCtD
Methyldopa—Arthralgia—Prednisone—systemic scleroderma	0.000288	0.00101	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000286	0.001	CcSEcCtD
Methyldopa—Mental disorder—Methotrexate—systemic scleroderma	0.000284	0.000999	CcSEcCtD
Methyldopa—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000279	0.000979	CcSEcCtD
Methyldopa—Nausea—Lisinopril—systemic scleroderma	0.000276	0.00097	CcSEcCtD
Methyldopa—Oedema—Prednisone—systemic scleroderma	0.000276	0.000969	CcSEcCtD
Methyldopa—Infection—Prednisone—systemic scleroderma	0.000274	0.000963	CcSEcCtD
Methyldopa—Nervous system disorder—Prednisone—systemic scleroderma	0.000271	0.000951	CcSEcCtD
Methyldopa—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000269	0.000946	CcSEcCtD
Methyldopa—Skin disorder—Prednisone—systemic scleroderma	0.000268	0.000942	CcSEcCtD
Methyldopa—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000259	0.000909	CcSEcCtD
Methyldopa—Rash—Mycophenolate mofetil—systemic scleroderma	0.000257	0.000902	CcSEcCtD
Methyldopa—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000256	0.000901	CcSEcCtD
Methyldopa—Headache—Mycophenolate mofetil—systemic scleroderma	0.000255	0.000896	CcSEcCtD
Methyldopa—Leukopenia—Methotrexate—systemic scleroderma	0.000253	0.000889	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000251	0.000883	CcSEcCtD
Methyldopa—Paraesthesia—Prednisone—systemic scleroderma	0.000248	0.000871	CcSEcCtD
Methyldopa—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000242	0.00085	CcSEcCtD
Methyldopa—Arthralgia—Methotrexate—systemic scleroderma	0.000241	0.000845	CcSEcCtD
Methyldopa—Myalgia—Methotrexate—systemic scleroderma	0.000241	0.000845	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000239	0.000839	CcSEcCtD
Methyldopa—Constipation—Prednisone—systemic scleroderma	0.000236	0.000829	CcSEcCtD
Methyldopa—Infection—Methotrexate—systemic scleroderma	0.000229	0.000805	CcSEcCtD
Methyldopa—Nervous system disorder—Methotrexate—systemic scleroderma	0.000226	0.000795	CcSEcCtD
Methyldopa—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000226	0.000793	CcSEcCtD
Methyldopa—Skin disorder—Methotrexate—systemic scleroderma	0.000224	0.000787	CcSEcCtD
Methyldopa—Body temperature increased—Prednisone—systemic scleroderma	0.000218	0.000766	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.00021	0.000738	CcSEcCtD
Methyldopa—Paraesthesia—Methotrexate—systemic scleroderma	0.000207	0.000728	CcSEcCtD
Methyldopa—Hypersensitivity—Prednisone—systemic scleroderma	0.000203	0.000714	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000199	0.000699	CcSEcCtD
Methyldopa—Asthenia—Prednisone—systemic scleroderma	0.000198	0.000696	CcSEcCtD
Methyldopa—Diarrhoea—Prednisone—systemic scleroderma	0.000189	0.000663	CcSEcCtD
Methyldopa—Dizziness—Prednisone—systemic scleroderma	0.000182	0.000641	CcSEcCtD
Methyldopa—Body temperature increased—Methotrexate—systemic scleroderma	0.000182	0.00064	CcSEcCtD
Methyldopa—Vomiting—Prednisone—systemic scleroderma	0.000175	0.000616	CcSEcCtD
Methyldopa—Rash—Prednisone—systemic scleroderma	0.000174	0.000611	CcSEcCtD
Methyldopa—Dermatitis—Prednisone—systemic scleroderma	0.000174	0.000611	CcSEcCtD
Methyldopa—Headache—Prednisone—systemic scleroderma	0.000173	0.000607	CcSEcCtD
Methyldopa—Hypersensitivity—Methotrexate—systemic scleroderma	0.00017	0.000597	CcSEcCtD
Methyldopa—Asthenia—Methotrexate—systemic scleroderma	0.000165	0.000581	CcSEcCtD
Methyldopa—Nausea—Prednisone—systemic scleroderma	0.000164	0.000576	CcSEcCtD
Methyldopa—Diarrhoea—Methotrexate—systemic scleroderma	0.000158	0.000554	CcSEcCtD
Methyldopa—Dizziness—Methotrexate—systemic scleroderma	0.000153	0.000536	CcSEcCtD
Methyldopa—Vomiting—Methotrexate—systemic scleroderma	0.000147	0.000515	CcSEcCtD
Methyldopa—Rash—Methotrexate—systemic scleroderma	0.000145	0.000511	CcSEcCtD
Methyldopa—Dermatitis—Methotrexate—systemic scleroderma	0.000145	0.00051	CcSEcCtD
Methyldopa—Headache—Methotrexate—systemic scleroderma	0.000144	0.000508	CcSEcCtD
Methyldopa—Nausea—Methotrexate—systemic scleroderma	0.000137	0.000481	CcSEcCtD
